Or­p­hazyme runs in­to an­oth­er set­back as Eu­rope ap­pears un­like­ly to ap­prove its FDA-re­ject­ed drug

The hits just keep on com­ing for Or­p­hazyme.

Less than a month af­ter its lat­est CEO an­nounced he will de­part in April for an­oth­er Dan­ish com­pa­ny, Or­p­hazyme re­port­ed Wednes­day af­ter­noon that the EMA is un­like­ly to ap­prove its ap­pli­ca­tion for a rare ge­net­ic con­di­tion known as Nie­mann-Pick dis­ease Type C. The biotech said it re­ceived a no­tice from CHMP in­di­cat­ing it will vote neg­a­tive­ly de­spite what it claimed was pos­i­tive feed­back.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER